Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition.

Wielgos ME, Zhang Z, Rajbhandari R, Cooper TS, Zeng L, Forero A, Esteva FJ, Osborne CK, Schiff R, LoBuglio AF, Nozell SE, Yang ES.

Mol Cancer Ther. 2018 May;17(5):921-930. doi: 10.1158/1535-7163.MCT-17-0302. Epub 2018 Mar 28.

2.

Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes.

Forero A, Li Y, Chen D, Grizzle WE, Updike KL, Merz ND, Downs-Kelly E, Burwell TC, Vaklavas C, Buchsbaum DJ, Myers RM, LoBuglio AF, Varley KE.

Cancer Immunol Res. 2016 May;4(5):390-9. doi: 10.1158/2326-6066.CIR-15-0243. Epub 2016 Mar 15.

3.

PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers.

Stanley J, Klepczyk L, Keene K, Wei S, Li Y, Forero A, Grizzle W, Wielgos M, Brazelton J, LoBuglio AF, Yang ES.

Breast Cancer Res Treat. 2015 Apr;150(3):569-79. doi: 10.1007/s10549-015-3359-6. Epub 2015 Apr 2.

4.

Recurrent read-through fusion transcripts in breast cancer.

Varley KE, Gertz J, Roberts BS, Davis NS, Bowling KM, Kirby MK, Nesmith AS, Oliver PG, Grizzle WE, Forero A, Buchsbaum DJ, LoBuglio AF, Myers RM.

Breast Cancer Res Treat. 2014 Jul;146(2):287-97. doi: 10.1007/s10549-014-3019-2. Epub 2014 Jun 15.

5.

Effect of niclosamide on basal-like breast cancers.

Londoño-Joshi AI, Arend RC, Aristizabal L, Lu W, Samant RS, Metge BJ, Hidalgo B, Grizzle WE, Conner M, Forero-Torres A, Lobuglio AF, Li Y, Buchsbaum DJ.

Mol Cancer Ther. 2014 Apr;13(4):800-11. doi: 10.1158/1535-7163.MCT-13-0555. Epub 2014 Feb 19.

6.

Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma.

Vaklavas C, Meredith RF, Shen S, Knox SJ, Micallef IN, Shah JJ, LoBuglio AF, Forero-Torres A.

Cancer Biother Radiopharm. 2013 Jun;28(5):370-9. doi: 10.1089/cbr.2012.1387. Epub 2013 Mar 26.

PMID:
23530878
7.

HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair.

Nowsheen S, Cooper T, Bonner JA, LoBuglio AF, Yang ES.

Cancer Res. 2012 Sep 15;72(18):4796-806. doi: 10.1158/0008-5472.CAN-12-1287.

8.

Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma.

Forero-Torres A, Bartlett N, Beaven A, Myint H, Nasta S, Northfelt DW, Whiting NC, Drachman JG, Lobuglio AF, Moskowitz CH.

Leuk Lymphoma. 2013 Feb;54(2):277-83. doi: 10.3109/10428194.2012.710328. Epub 2012 Sep 8.

PMID:
22775314
9.

Cellular model of Warburg effect identifies tumor promoting function of UCP2 in breast cancer and its suppression by genipin.

Ayyasamy V, Owens KM, Desouki MM, Liang P, Bakin A, Thangaraj K, Buchsbaum DJ, LoBuglio AF, Singh KK.

PLoS One. 2011;6(9):e24792. doi: 10.1371/journal.pone.0024792. Epub 2011 Sep 15.

10.

Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity.

Londoño-Joshi AI, Oliver PG, Li Y, Lee CH, Forero-Torres A, LoBuglio AF, Buchsbaum DJ.

Breast Cancer Res Treat. 2012 Jun;133(2):437-45. doi: 10.1007/s10549-011-1763-0. Epub 2011 Sep 14.

11.

Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer.

Nowsheen S, Bonner JA, Lobuglio AF, Trummell H, Whitley AC, Dobelbower MC, Yang ES.

PLoS One. 2011;6(8):e24148. doi: 10.1371/journal.pone.0024148. Epub 2011 Aug 30.

12.

Effect of anti-DR5 and chemotherapy on basal-like breast cancer.

Oliver PG, LoBuglio AF, Zhou T, Forero A, Kim H, Zinn KR, Zhai G, Li Y, Lee CH, Buchsbaum DJ.

Breast Cancer Res Treat. 2012 Jun;133(2):417-26. doi: 10.1007/s10549-011-1755-0. Epub 2011 Sep 7.

13.

Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma.

Shen S, Forero A, Meredith RF, LoBuglio AF.

Cancer Biother Radiopharm. 2011 Feb;26(1):127-33. doi: 10.1089/cbr.2010.0864.

PMID:
21355784
14.

Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.

Forero-Torres A, Saleh MN, Galleshaw JA, Jones CF, Shah JJ, Percent IJ, Nabell LM, Carpenter JT, Falkson CI, Krontiras H, Urist MM, Bland KI, De Los Santos JF, Meredith RF, Caterinicchia V, Bernreuter WK, O'Malley JP, Li Y, LoBuglio AF.

Clin Breast Cancer. 2010 Aug 1;10(4):275-80. doi: 10.3816/CBC.2010.n.035.

15.

Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.

Shen S, Forero A, Meredith RF, Shah JJ, Knox SJ, Wiseman GA, Usrey ME, Lobuglio AF.

J Nucl Med. 2010 Jan;51(1):150-7. doi: 10.2967/jnumed.109.066597. Epub 2009 Dec 15.

16.

Epithelial transformation by KLF4 requires Notch1 but not canonical Notch1 signaling.

Liu Z, Teng L, Bailey SK, Frost AR, Bland KI, LoBuglio AF, Ruppert JM, Lobo-Ruppert SM.

Cancer Biol Ther. 2009 Oct;8(19):1840-51.

17.

Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model.

Frederick PJ, Kendrick JE, Straughn JM Jr, Della Manna DL, Oliver PG, Lin HY, Grizzle WE, Stockard CR, Alvarez RD, Zhou T, LoBuglio AF, Buchsbaum DJ.

Int J Gynecol Cancer. 2009 Jul;19(5):814-9. doi: 10.1111/IGC.0b013e3181a2a003.

PMID:
19574765
18.

Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.

Oliver PG, LoBuglio AF, Zinn KR, Kim H, Nan L, Zhou T, Wang W, Buchsbaum DJ.

Clin Cancer Res. 2008 Apr 1;14(7):2180-9. doi: 10.1158/1078-0432.CCR-07-1392.

19.

TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth.

Derosier LC, Vickers SM, Zinn KR, Huang Z, Wang W, Grizzle WE, Sellers J, Stockard CR Jr, Zhou T, Oliver PG, Arnoletti P, Lobuglio AF, Buchsbaum DJ.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3198-207.

20.

Hedgehog pathway expression in heterogeneous pancreatic adenocarcinoma: implications for the molecular analysis of clinically available biopsies.

Steg A, Vickers SM, Eloubeidi M, Wang W, Eltoum IA, Grizzle WE, Saif MW, Lobuglio AF, Frost AR, Johnson MR.

Diagn Mol Pathol. 2007 Dec;16(4):229-37.

PMID:
18043287
21.

Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer.

Meredith RF, Buchsbaum DJ, Alvarez RD, LoBuglio AF.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5643s-5645s. Review.

22.

Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma.

Shah J, Wang W, Harrough VD, Saville W, Meredith R, Shen S, Mueh J, Lister J, Jasthy S, Maggass G, McKay C, Krumdieck R, Tharp M, Winter C, Gregory S, Buchholz W, Awasthi S, Jacobs S, Chung H, Egner J, Lobuglio AF, Forero A.

Leuk Lymphoma. 2007 Sep;48(9):1736-44.

PMID:
17786709
23.

TRAIL-receptor antibodies as a potential cancer treatment.

Buchsbaum DJ, Forero-Torres A, LoBuglio AF.

Future Oncol. 2007 Aug;3(4):405-9. Review.

PMID:
17661715
24.

Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model.

Estes JM, Oliver PG, Straughn JM Jr, Zhou T, Wang W, Grizzle WE, Alvarez RD, Stockard CR, LoBuglio AF, Buchsbaum DJ.

Gynecol Oncol. 2007 May;105(2):291-8. Epub 2007 Feb 15.

PMID:
17303227
25.

A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma.

Forero A, Shah J, Carlisle R, Triozzi PL, LoBuglio AF, Wang WQ, Fujimori M, Conry RM.

Cancer Biother Radiopharm. 2006 Dec;21(6):561-8.

PMID:
17257071
26.

Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity.

Triozzi PL, Shah JJ, Wang WQ, Aldrich W, Edberg JC, Su K, Carlisle R, Conry R, LoBuglio AF, Forero A.

Cancer Biother Radiopharm. 2006 Dec;21(6):553-60.

PMID:
17257070
27.

TRAIL receptor-targeted therapy.

Buchsbaum DJ, Zhou T, Lobuglio AF.

Future Oncol. 2006 Aug;2(4):493-508. Review.

PMID:
16922616
28.

Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma.

Steg A, Wang W, Blanquicett C, Grunda JM, Eltoum IA, Wang K, Buchsbaum DJ, Vickers SM, Russo S, Diasio RB, Frost AR, LoBuglio AF, Grizzle WE, Johnson MR.

J Mol Diagn. 2006 Feb;8(1):76-83.

29.

Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.

Buchsbaum DJ, Khazaeli MB, Axworthy DB, Schultz J, Chaudhuri TR, Zinn KR, Carpenter M, LoBuglio AF.

Clin Cancer Res. 2005 Nov 15;11(22):8180-5.

30.

Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.

Rogers BE, Roberson PL, Shen S, Khazaeli MB, Carpenter M, Yokoyama S, Brechbiel MW, LoBuglio AF, Buchsbaum DJ.

Cancer Biother Radiopharm. 2005 Oct;20(5):502-13. Erratum in: Cancer Biother Radiopharm. 2005 Dec;20(6):671.

31.

Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.

Forero A, Meredith RF, Khazaeli MB, Shen S, Grizzle WE, Carey D, Busby E, LoBuglio AF, Robert F.

Cancer Biother Radiopharm. 2005 Oct;20(5):467-78.

PMID:
16248762
32.

Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.

Forero-Torres A, Shen S, Breitz H, Sims RB, Axworthy DB, Khazaeli MB, Chen KH, Percent I, Besh S, LoBuglio AF, Meredith RF.

Cancer Biother Radiopharm. 2005 Aug;20(4):379-90.

PMID:
16114986
33.

Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse.

Triozzi PL, Aldrich W, Allen KO, Carlisle RR, LoBuglio AF, Conry RM.

J Immunother. 2005 Jul-Aug;28(4):382-8.

PMID:
16000957
34.

Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma.

Triozzi PL, Allen KO, Carlisle RR, Craig M, LoBuglio AF, Conry RM.

Clin Cancer Res. 2005 Jun 1;11(11):4168-75.

35.

Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.

Shen S, Forero A, LoBuglio AF, Breitz H, Khazaeli MB, Fisher DR, Wang W, Meredith RF.

J Nucl Med. 2005 Apr;46(4):642-51.

36.

Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma.

Triozzi PL, Strong TV, Bucy RP, Allen KO, Carlisle RR, Moore SE, Lobuglio AF, Conry RM.

Hum Gene Ther. 2005 Jan;16(1):91-100.

PMID:
15703492
37.

The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3.

Kamradt MC, Lu M, Werner ME, Kwan T, Chen F, Strohecker A, Oshita S, Wilkinson JC, Yu C, Oliver PG, Duckett CS, Buchsbaum DJ, LoBuglio AF, Jordan VC, Cryns VL.

J Biol Chem. 2005 Mar 25;280(12):11059-66. Epub 2005 Jan 14.

38.

ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas.

de Bono JS, Tolcher AW, Forero A, Vanhove GF, Takimoto C, Bauer RJ, Hammond LA, Patnaik A, White ML, Shen S, Khazaeli MB, Rowinsky EK, LoBuglio AF.

Clin Cancer Res. 2004 Nov 15;10(22):7555-65.

39.

Nuclear localization of KLF4 is associated with an aggressive phenotype in early-stage breast cancer.

Pandya AY, Talley LI, Frost AR, Fitzgerald TJ, Trivedi V, Chakravarthy M, Chhieng DC, Grizzle WE, Engler JA, Krontiras H, Bland KI, LoBuglio AF, Lobo-Ruppert SM, Ruppert JM.

Clin Cancer Res. 2004 Apr 15;10(8):2709-19.

40.

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.

Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J, Goris ML, Picozzi VJ, Axworthy DB, Breitz HB, Sims RB, Ghalie RG, Shen S, Meredith RF.

Blood. 2004 Jul 1;104(1):227-36. Epub 2004 Mar 2.

PMID:
14996706
41.

History of antibody therapy for non-Hodgkin's lymphoma.

Forero A, Lobuglio AF.

Semin Oncol. 2003 Dec;30(6 Suppl 17):1-5. Review.

PMID:
14710396
42.

A novel monoclonal antibody design for radioimmunotherapy.

Forero A, Meredith RF, Khazaeli MB, Carpenter DM, Shen S, Thornton J, Schlom J, LoBuglio AF.

Cancer Biother Radiopharm. 2003 Oct;18(5):751-9.

PMID:
14629823
43.

Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.

Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S, Carpenter M, LoBuglio AF.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3731-41.

45.

Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy.

Shen S, Meredith RF, Duan J, Brezovich I, Khazaeli MB, LoBuglio AF.

Cancer Biother Radiopharm. 2003 Apr;18(2):209-15.

PMID:
12804046
46.

A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma.

Posey JA, Ng TC, Yang B, Khazaeli MB, Carpenter MD, Fox F, Needle M, Waksal H, LoBuglio AF.

Clin Cancer Res. 2003 Apr;9(4):1323-32.

47.

Invited commentary: targeting of 125I-labeled B lymphocyte stimulator.

Buchsbaum DJ, LoBuglio AF.

J Nucl Med. 2003 Mar;44(3):434-6. No abstract available.

48.

A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors.

Posey JA, Khazaeli MB, Bookman MA, Nowrouzi A, Grizzle WE, Thornton J, Carey DE, Lorenz JM, Sing AP, Siegall CB, LoBuglio AF, Saleh MN.

Clin Cancer Res. 2002 Oct;8(10):3092-9.

49.

A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.

Alvarez RD, Huh WK, Khazaeli MB, Meredith RF, Partridge EE, Kilgore LC, Grizzle WE, Shen S, Austin JM, Barnes MN, Carey D, Schlom J, LoBuglio AF.

Clin Cancer Res. 2002 Sep;8(9):2806-11.

50.

Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.

Conry RM, Curiel DT, Strong TV, Moore SE, Allen KO, Barlow DL, Shaw DR, LoBuglio AF.

Clin Cancer Res. 2002 Sep;8(9):2782-7.

Supplemental Content

Loading ...
Support Center